Armistice Capital, Llc - Jan 7, 2022 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Director, 10%+ Owner
Signature
ARMISTICE CAPITAL, LLC, Name: /s/ Steven Boyd, Title: Managing Member
Stock symbol
AVTX
Transactions as of
Jan 7, 2022
Transactions value $
$642,931
Form type
4
Date filed
1/11/2022, 05:18 PM
Previous filing
Sep 17, 2021
Next filing
Jan 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTX Common Stock Purchase $143K +138K +0.31% $1.04 45.1M Jan 7, 2022 See Footnote F1, F2
transaction AVTX Common Stock Purchase $485K +491K +1.09% $0.99 45.6M Jan 10, 2022 See Footnote F1, F3
transaction AVTX Common Stock Purchase $15.3K +16K +0.04% $0.96 45.6M Jan 11, 2022 See Footnote F1, F4
holding AVTX Common Stock 412K Jan 7, 2022 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities of Avalo Therapeutics, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.0097 to $1.0811, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9733 to $1.0064, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9484 to $0.9795, inclusive.
F5 These shares are directly owned by Mr. Boyd in his personal capacity.